Antonino Suarato

This inventor holds 55 USPTO granted patents, primarily in Anthracycline Derivatives (CPC class 536-). Top assignees: Pharmacia & Upjohn, Farmitalia Carlo Erba S.r.l., Farmitalia Carlo Erba. Active years: 1977-2003.

USPTO Granted Patents = 55

% Patents Active = 94.5

Average Co-Inventor Count = 4.3

ph-index = 13

Forward Citations = 598(Granted Patents)

Forward Citations (Not Self Cited) = 569(Dec 10, 2025)

Inventors with similar research interests:

Company Filing History:

Farmitalia Carlo Erba S.r.l.

patents

11 out of 208

Farmitalia Carlo Erba

patents

4. 10 out of 48

Societa' Farmaceutici Italia

patents

5. 2 out of 26

Pharmacia Italia S.p.a.

patents

6. 1 out of 220

Pharmacia Corporation

patents

Years Active: 1977-2003

Loading Chart...

Areas of Expertise:

Anthracycline Derivatives

Polymer-Bound Compounds

Anti-Tumor Compositions

Camptothecin Derivatives

Amino Anthracyclinone

Fluoro Labelled Derivatives

Bioactive Agents

Doxorubicin Derivatives

Pharmaceutical Compositions

Glycosides

Morpholine Derivatives

Aza-Anthracyclinone

55 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6593303 - Anti-tumor synergetic composition (2003-07-15),

2. 6586428 - Combined preparations comprising morpholine anthracyclines and anticancer agent (2003-07-01),

3. 6537990 - Combined preparations comprising morpholine anthracyclines and anticancer agent (2003-03-25),

4. 6403563 - Antitumor composition containing a synergistic combination of an anthracycline derivative with a camptothecin derivate (2002-06-11),

5. 6376617 - Bioactive derivatives of camptothecin (2002-04-23),

6. 6328953 - Polymeric derivatives of camptothecins (2001-12-11),

7. 6268362 - Amino anthracyclinone derivatives and their use in the treatment of amyloidosis (2001-07-31),

8. 6258786 - 13-dihydro-3′ aziridino anthracyclines (2001-07-10),

9. 6245358 - Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation (2001-06-12),

10. 6194422 - Anthracycline derivatives (2001-02-27),

11. 6103700 - Fluoro labelled anthracyclinone and anthracycline derivatives (2000-08-15),

12. 6096888 - Anthracyclinone derivatives and their use in amyloidosis (2000-08-01),

13. 5998615 - Anthracyclinone derivatives (1999-12-07),

14. 5985887 - Aza-anthracyclinone derivatives (1999-11-16),

15. 5776458 - Anthracycline-conjugates (1998-07-07),

Title: The Innovative Contributions of Antonino Suarato

Introduction

Antonino Suarato, based in Milan, Italy, is a notable innovator in the field of oncology, holding an impressive portfolio of 55 patents. His groundbreaking work primarily focuses on the development of anti-cancer therapies, showcasing his dedication to advancing medical science and improving patient outcomes.

Latest Patents

Among his latest patents is the "Anti-tumor synergetic composition," which involves a combined use of specific derivatives of daunorubicin along with anti-neoplastic compounds. This invention aims to enhance the treatment of tumors and prevent metastasis by inhibiting angiogenesis. Another significant patent is for "Combined preparations comprising morpholine anthracyclines and anticancer agent." This innovation involves using a morpholinyl anthracycline in conjunction with various anticancer agents, making it particularly useful for treating primary or metastatic liver cancer.

Career Highlights

Suarato's professional journey includes significant tenure at prominent pharmaceutical companies such as Pharmacia & Upjohn and Farmitalia Carlo Erba. His experience in these skilled environments has allowed him to contribute effectively to drug development and cancer treatment innovations.

Collaborations

Collaboration has been a key aspect of Suarato's career, and he has worked alongside distinguished individuals such as Michele Caruso and Paolo Masi. These collaborations have fostered an environment where innovative ideas can flourish, ultimately leading to the development of impactful therapies.

Conclusion

Antonino Suarato's contributions to oncology through his numerous patents and collaborations highlight his significant role in advancing medical research. His innovative spirit and dedication to finding effective cancer treatments continue to inspire upcoming generations in the scientific community.